Advertisement

Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia

  • Hidefumi HiramatsuEmail author
  • Souichi Adachi
  • Katsutsugu Umeda
  • Itaru Kato
  • Lamis Eldjerou
  • Andrea Chassot Agostinho
  • Kazuto Natsume
  • Kota Tokushige
  • Yoko Watanabe
  • Stephan A. Grupp
Original Article
  • 113 Downloads

Abstract

Tisagenlecleucel is an autologous T cell genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor. Here, we present the efficacy and safety of tisagenlecleucel in a subgroup of Japanese patients with relapsed/refractory (r/r) B-cell acute lymphoblastic leukemia (ALL). ELIANA was a single-arm, open-label, multicenter, phase 2 study. Patients were aged ≥ 3 years at screening to ≤ 21 years at the time of diagnosis, and had ≥ 5% lymphoblasts in bone marrow at screening. Primary endpoint was overall remission rate [ORR; complete remission (CR) + CR with incomplete blood recovery (CRi)] within 3 months after infusion. As of April 13, 2018, eight patients were enrolled and six had been infused. ORR was 66.7% (95% confidence interval 22.3–95.7); three patients achieved CR and one patient had CRi. All patients with CR/CRi were negative for minimal residual disease. One patient had CR/CRi lasting 19.5 + months. Cytokine release syndrome (CRS) and neurological events occurred in 83% and 17% of patients, respectively. CRS resolved with anti-cytokine therapy and supportive care. Two deaths occurred due to disease progression. No cases of cerebral edema were observed. Tisagenlecleucel produced high remission rates and durable responses offering a new treatment option for Japanese pediatric and young adults with r/r B-ALL.

Keywords

Tisagenlecleucel CAR T Acute lymphoblastic leukemia ELIANA CTL019 

Notes

Acknowledgements

We thank the patients and their families, the study investigators, and the study site personnel for their participations and contributions to this study. The current affiliation of Kazuto Natsume is AbbVie GK. We thank Rama Mylapuram (Novartis Healthcare Pvt. Ltd.) for medical editorial assistance with this paper.

Funding

This study was sponsored by Novartis Pharmaceuticals Corporation and Novartis Pharma K.K.

Compliance with ethical standards

Conflict of interest

IK reports research Grants from Novartis. SAG has received research and/or clinical trial support from Novartis, Servier and Kite. SAG reports consulting, member of study steering committees, or scientific/clinical advisory boards: Novartis, Cellectis, Adaptimmune, Eureka, TCR2, Juno, GlaxoSmithKline, Vertex, Cure Genetics, Humanigen, and Roche. LE, ACA, KN, KT, and YW are employees of Novartis. All other authors declare no competing interests.

References

  1. 1.
    Koh K, Kato M, Saito AM, Kada A, Kawasaki H, Okamoto Y, et al. Phase II/III study in children and adolescents with newly diagnosed B-cell precursor acute lymphoblastic leukemia: protocol for a nationwide multicenter trial in Japan. Jpn J Clin Oncol. 2018;48(7):684–91.CrossRefGoogle Scholar
  2. 2.
    Chihara D, Ito H, Matsuda T, Shibata A, Katsumi A, Nakamura S, et al. Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol. 2014;164(4):536–45.CrossRefGoogle Scholar
  3. 3.
    Miranda-Filho A, Pineros M, Ferlay J, Soerjomataram I, Monnereau A, Bray F. Epidemiological patterns of leukaemia in 184 countries: a population-based study. Lancet Haematol. 2018;5(1):e14–24.CrossRefGoogle Scholar
  4. 4.
    Takeuchi J, Kusumoto S, Akiyama H, Kanda Y, Izutsu K. JSH guideline for tumors of hematopoietic and lymphoid tissues-leukemia: 3. Acute lymphoblastic leukemia/lymphoblastic lymphoma (ALL/LBL). Int J Hematol. 2017;106(6):732–47.CrossRefGoogle Scholar
  5. 5.
    Nguyen K, Devidas M, Cheng SC, La M, Raetz EA, Carroll WL, et al. Factors influencing survival after relapse from acute lymphoblastic leukemia: a Children’s Oncology Group study. Leukemia. 2008;22(12):2142–50.CrossRefGoogle Scholar
  6. 6.
    Sun W, Malvar J, Sposto R, Verma A, Wilkes JJ, Dennis R, et al. Outcome of children with multiply relapsed B-cell acute lymphoblastic leukemia: a therapeutic advances in childhood leukemia & lymphoma study. Leukemia. 2018;32(11):2316–25.CrossRefGoogle Scholar
  7. 7.
    Crotta A, Zhang J, Keir C. Survival after stem-cell transplant in pediatric and young-adult patients with relapsed and refractory B-cell acute lymphoblastic leukemia. Curr Med Res Opin. 2018;34(3):435–40.CrossRefGoogle Scholar
  8. 8.
    Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018;60(1):4–12.CrossRefGoogle Scholar
  9. 9.
    Brown PA, Shah B, Fathi A, Wieduwilt M, Advani A, Aoun P, et al. NCCN guidelines insights: acute lymphoblastic leukemia, version 1.2017. J Natl Compr Cancer Netw. 2017;15(9):1091–102.CrossRefGoogle Scholar
  10. 10.
    Milone MC, Fish JD, Carpenito C, Carroll RG, Binder GK, Teachey D, et al. Chimeric receptors containing CD137 signal transduction domains mediate enhanced survival of T cells and increased antileukemic efficacy in vivo. Mol Ther. 2009;17(8):1453–64.CrossRefGoogle Scholar
  11. 11.
    Maude SL, Laetsch TW, Buechner J, Rives S, Boyer M, Bittencourt H, et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N Engl J Med. 2018;378(5):439–48.CrossRefGoogle Scholar
  12. 12.
    Mueller KT, Waldron E, Grupp SA, Levine JE, Laetsch TW, Pulsipher MA, et al. Clinical pharmacology of tisagenlecleucel in B-cell acute lymphoblastic leukemia. Clin Cancer Res. 2018;24(24):6175–84.CrossRefGoogle Scholar
  13. 13.
    Neelapu SS, Locke FL, Bartlett NL, Lekakis LJ, Miklos DB, Jacobson CA, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–44.CrossRefGoogle Scholar
  14. 14.
    Porter D, Frey N, Wood PA, Weng Y, Grupp SA. Grading of cytokine release syndrome associated with the CAR T cell therapy tisagenlecleucel. J Hematol Oncol. 2018;11(1):35.CrossRefGoogle Scholar
  15. 15.
    Porter DL, Hwang WT, Frey NV, Lacey SF, Shaw PA, Loren AW, et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med. 2015;7(303):303ra139.CrossRefGoogle Scholar
  16. 16.
    Abramson JS, Gordon LI, Palomba ML, et al. Updated safety and long term clinical outcomes in TRANSCEND NHL 001, pivotal trial of lisocabtagene maraleucel (JCAR017) in R/R aggressive NHL. J Clin Oncol. 2018;36(suppl):abstr 7505.CrossRefGoogle Scholar
  17. 17.
    Schuster SJ, Bishop MR, Tam C, Borchmann P, Jaeger U, Waller EK, et al. Sustained disease control for adult patients with relapsed or refractory diffuse large B-cell lymphoma: an updated analysis of juliet, a global pivotal phase 2 trial of tisagenlecleucel. Blood. 2018;132(Suppl 1):1684.CrossRefGoogle Scholar
  18. 18.
    Le RQ, Li L, Yuan W, Shord SS, Nie L, Habtemariam BA, et al. FDA approval summary: tocilizumab for treatment of chimeric antigen receptor T cell-induced severe or life-threatening cytokine release syndrome. Oncologist. 2018;23(8):943–7.CrossRefGoogle Scholar

Copyright information

© Japanese Society of Hematology 2019

Authors and Affiliations

  • Hidefumi Hiramatsu
    • 1
    Email author
  • Souichi Adachi
    • 2
  • Katsutsugu Umeda
    • 1
  • Itaru Kato
    • 1
  • Lamis Eldjerou
    • 3
  • Andrea Chassot Agostinho
    • 3
  • Kazuto Natsume
    • 4
  • Kota Tokushige
    • 4
  • Yoko Watanabe
    • 4
  • Stephan A. Grupp
    • 5
    • 6
  1. 1.Department of Pediatrics, Graduate School of MedicineKyoto UniversityKyotoJapan
  2. 2.Human Health Sciences, Graduate School of MedicineKyoto UniversityKyotoJapan
  3. 3.Novartis Pharmaceuticals Co.East HanoverUSA
  4. 4.Novartis Pharma KKTokyoJapan
  5. 5.Division of OncologyChildren’s Hospital of PhiladelphiaPhiladelphiaUSA
  6. 6.Department of Pediatrics, Perelman School of MedicineUniversity of PennsylvaniaPhiladelphiaUSA

Personalised recommendations